Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by AKAMPION
< Previous
1
2
3
Next >
Atopia Therapeutics Reports Preclinical Proof-of-Concept of Lead Compound ATP-R13 in Atopic Dermatitis and Strengthens Patent Protection
January 20, 2026
From
AKAMPION
Via
GlobeNewswire
Mabylon AG Initiates Phase I Clinical Trial of Lead Compound MY006 for the Treatment of Peanut Allergy
December 11, 2025
From
AKAMPION
Via
GlobeNewswire
tiakis Biotech Successfully Completes Data Package to Advance Tiprelestat into Phase II clinical trial in PAH
December 02, 2025
From
AKAMPION
Via
GlobeNewswire
Captain T Cell Closes Financing Round to Advance its Proprietary, Next-Generation TCR-T Pipeline Into the Clinic
November 17, 2025
From
AKAMPION
Via
GlobeNewswire
selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
October 21, 2025
From
AKAMPION
Via
GlobeNewswire
ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors
October 20, 2025
From
AKAMPION
Via
GlobeNewswire
Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund
October 15, 2025
From
AKAMPION
Via
GlobeNewswire
Stanford University Secures NIH Grant to Advance tiakis Biotech´s Elafin (Tiprelestat) Through a U.S. Phase II Trial in Pulmonary Arterial Hypertension
September 08, 2025
From
AKAMPION
Via
GlobeNewswire
BellaSeno Establishes High-Profile Clinical Advisory Board
August 18, 2025
From
AKAMPION
Via
GlobeNewswire
Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Concept
August 12, 2025
From
AKAMPION
Via
GlobeNewswire
MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy
July 29, 2025
From
AKAMPION
Via
GlobeNewswire
Ebenbuild Secures Euro 2.3 Million EIC Grant to Scale Digital Twin Platform for Respiratory Health
July 02, 2025
From
AKAMPION
Via
GlobeNewswire
Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue Sarcomas
June 24, 2025
From
AKAMPION
Via
GlobeNewswire
Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients
June 17, 2025
From
AKAMPION
Via
GlobeNewswire
tiakis Biotech AG Announces Appointment of ex-Actelion Executive Christoph Schmidt as New Supervisory Board Member
May 21, 2025
From
AKAMPION
Via
GlobeNewswire
Thermosome Receives U.S. Orphan Drug Designation for Lead Compound THE001, Expands Patent Estate
May 12, 2025
From
AKAMPION
Via
GlobeNewswire
Dr. Stephan Rietiker elected as new Chairman of the Board of MetrioPharm AG
April 23, 2025
From
AKAMPION
Via
GlobeNewswire
1STBIO and LigaChemBio Announce Strategic R&D and Licensing Option Agreement
April 22, 2025
From
AKAMPION
Via
GlobeNewswire
Four new members elected to the Board of Directors of MetrioPharm AG
April 17, 2025
From
AKAMPION
Via
GlobeNewswire
1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research
April 15, 2025
From
AKAMPION
Via
GlobeNewswire
Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development
April 09, 2025
From
AKAMPION
Via
GlobeNewswire
New Clinical Data on BellaSeno’s Novel, Resorbable Breast Implants Presented at The Aesthetic MEET 2025
March 24, 2025
From
AKAMPION
Via
GlobeNewswire
AMYRA Publishes Landmark Review Supporting New Gluten Digestion Approach for Celiac Disease
February 25, 2025
From
AKAMPION
Via
GlobeNewswire
BellaSeno Successfully Completes Two Clinical Trials with Novel, Resorbable Breast Implants
January 14, 2025
From
AKAMPION
Via
GlobeNewswire
tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
January 08, 2025
From
AKAMPION
Via
GlobeNewswire
Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark
January 07, 2025
From
AKAMPION
Via
GlobeNewswire
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
December 09, 2024
From
AKAMPION
Via
GlobeNewswire
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
December 04, 2024
From
AKAMPION
Via
GlobeNewswire
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
November 19, 2024
From
AKAMPION
Via
GlobeNewswire
Ebenbuild Appoints Charles A. Taylor, PhD as Chairman of the Board
November 11, 2024
From
AKAMPION
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today